logo

INDSWFTLAB vs JBCHEPHARM: Stock Comparison

IND SWIFT LABORATORIES LT vs JBCHEPHARMUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

IND SWIFT LABORATORIES LT shows a lower P/E and a higher net margin, while JBCHEPHARM shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDSWFTLAB leads 3; JBCHEPHARM leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDSWFTLABJBCHEPHARM

Valuation lens

What price are you paying?

Market CapContext only
₹3,002 Cr
₹0 Cr
P/E RatioINDSWFTLAB has the lower reading
51.3x ✓
54.59x
P/B RatioINDSWFTLAB has the lower reading
2.17x ✓
9.31x
EPSJBCHEPHARM has the higher reading
₹2.84
₹6.31 ✓
Book ValueContext only
₹159.15
₹259.05
Dividend YieldJBCHEPHARM has the higher reading
0%
0.88% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

P/E Ratio
INDSWFTLAB has a lower P/E
51.3x vs 54.59x
P/B Ratio
INDSWFTLAB has a lower P/B
2.17x vs 9.31x
EPS
JBCHEPHARM has higher earnings per share
₹6.31 vs ₹2.84
Dividend Yield
JBCHEPHARM has a higher dividend yield
0.88% vs 0%
Revenue Growth (TTM YoY)
JBCHEPHARM has faster revenue growth
-4.8% vs -66.6%
EPS Growth (TTM YoY)
JBCHEPHARM has faster EPS growth
-31% vs -94.8%
ROE
JBCHEPHARM has a higher ROE
16.7% vs 2.99%
ROCE
JBCHEPHARM has a higher ROCE
17.05% vs 4.37%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDSWFTLABJBCHEPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDSWFTLABJBCHEPHARM
Live Price₹345.35₹2,408.9
Day Change0.83%-3.87%
Volume2.7 L47.79 L
52-Week High₹424.75₹2,525.5
52-Week Low₹87.15₹1,675
Distance from 52W High-18.69%-4.62%

Valuation

MetricINDSWFTLABJBCHEPHARM
Market Cap₹3,002 Cr₹0 Cr
P/E Ratio51.3x54.59x
P/B Ratio2.17x9.31x
EPS₹2.84₹6.31
Book Value₹159.15₹259.05
Dividend Yield0%0.88%

Growth

MetricINDSWFTLABJBCHEPHARM
Revenue Growth (TTM YoY)-66.6%-4.8%
EPS Growth (TTM YoY)-94.8%-31%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricINDSWFTLABJBCHEPHARM
ROE2.99%16.7%
ROCE4.37%17.05%
Net Margin41.4%17.1%
Operating Margin7.87%23.33%
Debt to Equity0.01x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricINDSWFTLABJBCHEPHARM
Promoter Holding42.93%48.8%▲ 48.8 pp
FII Holding10.78%▲ 0.08 pp16.33%▲ 1.45 pp
DII Holding0.2%▲ 0.03 pp21.38%▼ 1.98 pp
Public Holding46.09%▼ 0.11 pp13.48%▼ 0.74 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IND SWIFT LABORATORIES LT and JBCHEPHARM.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.